Earnings
Coherus Plans 30% Staff Cut To Lower The Sales Needed To Cover Core Costs
Quarterly drug sales missed management's growth target, while cash runway excludes potential savings, milestones and overseas deals.
Coherus Oncology (CHRS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Quarterly drug sales missed management's growth target, while cash runway excludes potential savings, milestones and overseas deals.
SEC Filings
LOQTORZI sales rose 25%, but the cancer-drug company is narrowing development and targeting lower quarterly cash spending.
SEC Filings
The experimental antibody, paired with toripalimab and chemotherapy, showed a 75% confirmed response rate in a small interim cohort.